Expert Ratings for Milestone Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Milestone Pharmaceuticals (NASDAQ:MIST) stock, with 4 bullish and 1 somewhat bullish ratings. The average 12-month price target is $22.6, up 41.25% from the previous average of $16.
May 23, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Pharmaceuticals (MIST) has received positive ratings from 5 analysts, with an average 12-month price target of $22.6, a 41.25% increase from the previous target.
The article mentions that 5 analysts have rated Milestone Pharmaceuticals (MIST) stock positively, with an average 12-month price target of $22.6, which is a 41.25% increase from the previous average price target. This indicates a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100